Skip to main content
Menu

Posts tagged with "Toxicology"

  • Natural Products

    Sodium Benzoate Nonsense

    I don’t spend a lot of time on the blog swatting down idiotic ideas about chemicals. It’s a full time job, and (see next post) I already have a full time job. It’s also frustrating work, because the supply of idiocy is apparently beyond limit, and just when you think you’ve seen the most clueless… Read More
  • Cancer

    How to Know When a New Target is Really a New Target

    This is an excellent article, and the title is self-recommending: “Common Pitfalls in Preclinical Cancer Target Validation”. The abstract speaketh the truth: An alarming number of papers from laboratories nominating new cancer drug targets contain findings that cannot be reproduced by others or are simply not robust enough to justify dr… Read More
  • Cardiovascular Disease

    Thoughts on An Antibody Failure

    Talking with some drug discovery folks the other day, I said “You know, if you don’t hold your breath when your compound goes into tox testing, you haven’t been doing this stuff long enough”. Well, it’s pretty hard to hold your breath across a full tox study, but you know what I mean. There are… Read More
  • Life in the Drug Labs

    Pyridine Doesn’t Do What You Think It Does

    OK, this is not exactly a time-sensitive issue, but since I took a crack at one of the most prominent toxicology myths in the biology labs (ethidium bromide is not really all that bad, in case you missed it), I figured I should do the same for one of the persistent myths on the organic… Read More
  • Alzheimer's Disease

    A New Way to Make GSK3 Inhibitors

    Of the discovery of GSK3 (glycogen synthase kinase 3) inhibitors there has been no end. I first came across it as a target it about 1997, and even then, once I started reading the literature, I quickly felt as if I were late to the party. It’s been investigated for diabetes (and other metabolic diseases), Alzheimer’s… Read More
  • Clinical Trials

    Antibiotics Are Hard, Continued

    I wrote here about an ingenious synthetic effort into structurally diverse ketolide antibiotics, structures that need a lot of work to make them from the ground up. Well, I have one of those good-news/bad-news reports: it looks like synthetic work will definitely be needed in this area, because the latest clinical candidate in it has… Read More
  • Clinical Trials

    A Quiet And Sudden Exit for Amiselimod

    Here’s an example of a common behavior in this industry – and to be fair, in many others as well. Big deals are celebrated and press-released at the outset, but if things don’t work out, they end very quietly – as quietly as possible. Sometimes that’s not very possible at all, because a big Phase… Read More
  • Clinical Trials

    Revusiran’s Failure Revisited

    I wrote about Alnylam’s recent clinical disaster here, where they had to stop a Phase III siRNA therapy trial against a rare amyloidosis with cardiac complications. A reader sends along the link to this 2008 paper that suggests a possible reason for the excess deaths seen in the trial. The authors studied a range of different siRNA… Read More
  • Clinical Trials

    Alnylam Blindsided

    Alnylam, the big name in RNAi therapeutics, had an awful day of it yesterday, and is having another one today. More may be on the way. Rivusiran, their Phase III candidate for transthyretin amyloidosis (ATTR), has been abruptly pulled from trials. This is particularly out of the blue, since the company had just completed enrollment… Read More
  • Clinical Trials

    Cathepsin K: A Promising Target Fades Out

    Here’s another one for the file of huge, long, costly drug discovery efforts that came to nothing (and that no one outside the business ever hears about): cathepsin K inhibitors. I remember “Cat K” from my own (relatively brief) days in osteoporosis drug work some years ago. It’s a target that’s been around since the… Read More
...345...